News

Icon signals $8B full-year revenue midpoint as metabolic and obesity trial momentum builds

Discover Q2 2025 insights on ICON Public Limited Company (ICLR), featuring revenue growth, digital innovation, biotech partnerships, and cautious ...

ICON: Lower Guidance Downside And Expanded Repurchase Plan

ICON Public Limited Company is still off its highs and has some absolute valuation appeal. Click here to see why ICLR stock ...